BioNanomatrix awarded $2.08M for whole genome analyzer

March 17, 2009: BioNanomatrix Inc., a developer of nanoscale platforms for biomedical research, molecular diagnostics and personalized medicine, has received a Phase II grant from the National Human Genome Research Institute (NHGRI) of the US National Institutes of Health (NIH).

The grant is intended to support further commercial development of BioNanomatrix’s nanoscale whole-genome imaging and analysis platform. It follows the company’s successful completion of work under a similar Phase I grant for initial development of the technology.

The 30-month $2.08 million Small Business Investment Research (SBIR) award was made under the BioEngineering Nanotechnology Initiative, an interdisciplinary, multi-institutes consortium with the stated goal of supporting the development of nanotechnologies critical for enabling essential breakthroughs that may have tremendous potential for affecting biomedicine.

“We are pleased that the NIH has again recognized the potential of our unique approach by awarding us this Phase II grant for the commercial development of our integrated nanoscale whole genome imaging and analysis platform,” said Michael Boyce-Jacino, Ph.D., president and CEO of BioNanomatrix. “This additional funding will help support the commercial development of our potentially transformative technology.”

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.